

IN THE CLAIMS:

1-2. (Canceled)

3. (Previously presented) The method as claimed in claim 7, characterized in that the spasmolytic includes NO or an NO source as the further spasmolytic in a therapeutically effective amount.

4. (Currently amended) The method as claimed in claim 7, wherein the xenon and the further spasmolytic are used simultaneously, separately or sequentially in the treatment of coronary vasospasms or bronchial spasms.

5-6. (Canceled)

7. (Currently amended) A method of treating a patient characterized in that a xenon spasmolytic is provided in a form of a combination medicament comprising xenon selected from the group consisting of gaseous xenon and a xenon containing gas mixture, and a further spasmolytic, administering the xenon to a patient in a subanesthetic amount wherein the xenon containing gas mixture administered to the patient contains no more than 60% by volume of xenon and when the xenon containing gas mixture is metered into the patient's respiratory gas the combined gas supplied to the patient contains from 5 to 60% by volume xenon, administering the further spasmolytic orally or intravenously, and the combination medicament is administered to a patient as a medicament for a treatment of spasms, and selecting as a patient some one suffering from coronary vasospasms or bronchial spasms, and wherein the xenon is used with the intended purpose of acting as an effective coronary or bronchial spasmolytic.

8. (Previously presented) The method according to claim 7, wherein the combination medicament has a vasodilating effect in capillary or precapillary vascular systems of the human body.

9-17. (Canceled)

18. (Currently amended) The method according to claim 7, wherein the spasms are selected from the group consisting of bronchial spasms and coronary vasospasms and ~~cerebral vasospasms~~.